Biophytis SA announced the strengthening of its management team with the appointment of Chiara Baccelli to the newly created position of Director of Pharmaceutical Operations and Quality Assurance and the upcoming arrival of Nicolas Fellmann as Chief Financial Officer as of 22 May 2022. He will replace Philippe Rousseau who is leaving the company to pursue other projects. Chiara Baccelli, PharmD, PhD, MBA, holds more than 20 years of experience in the development and production of pharmaceutical products, especially from natural origins.

After a first experience in academic research, Chiara has worked during her career for UCB in Belgium, for the French group Delpharm, the company Bioprojet and also for the consulting firm IDD in France in collaboration with large pharmaceutical groups such as Boehringer Ingelheim, Ipsen, Sanofi, Nemera, Harmony Bioscience. She has covered different roles around the development of innovative products, from CMC to Quality Assurance and Control, Industrialization and Regulatory Affairs. She holds a PharmD from the University of Pisa in Italy, a PhD in Pharmaceutical and Biomedical Sciences from the Catholic University of Leuven in Belgium and a MBA in Innovation and Strategy from IRIIG in Lyon.

Besides, for personal reasons, Mr. Dimitri Bastis has decided to resign as member of the Company's Board of Directors.